Introduction Human Wharton's jelly (WJ) has become a preferred source of mesenchymal stem cells (MSCs) whose clinical applications are limited by the use of adequate xeno-free (XF), in vitro manipulation conditions. Therefore, the objective of our study was to characterize WJ-derived MSCs (WJ-MSCs), isolated by different methods and cultured in a commercially available, MSC XF medium, not least of all by investigating their endothelial differentiation

Introduction: The umbilical cord blood (UCB) and matrix (Wharton’s jelly, WJ) are rich sources of self-renewal, multiple-lineage differentiating cells, extensively proposed for cell replacement therapy. However, their ability to participate to cardiovascular tissue restoration has not been thoroughly elucidated. Objective: We employed a novel coculture system to investigate the capacity of human UCB-derived endothelial progenitor cells (EPCs) and

Wharton’s jelly (WJ) is a rich source of multiple-lineage differentiating cells, recently proposed for cell replacement therapy. However, their ability to integrate into the cardiac tissue has not been elucidated, yet. We employed in vitro cardiac transplantation models to investigate the capacity of a novel population of human WJ-derived mesenchymal stem cells (nMSCs) to integrate into both living and ischemic cardiac tissue. NMSCs were characterized

OBJECTIVE: The umbilical cord blood derived endothelial progenitor cells (EPCs) contribute to vascular regeneration in experimental models of ischemia. However, their ability participate to cardiovascular tissue restoration has not been elucidated, yet. We employed a novel coculture system to investigate whether human EPCs have the capacity to integrate into living and ischemic cardiac tissue, and participate to neovascularization. MATERIALS AND

Background: Preclinical studies of peripheral blood mononuclear cell (PBMC) transplantation conducted in a well-established canine hematopoietic cell transplantation (HCT) model have been successfully translated to human patients over the past 5 decades. Objective: We retrospectively investigated the safety and feasibility of PBMC apheresis in the canine model of HCT by analyzing apheresis parameters, cell yields, and the impacts of donor-related

We sought to determine whether wild-type hematopoietic cell transplantation directly into muscle could restore dystrophin expression in a relevant preclinical canine model of Duchenne muscular dystrophy. In recipients rendered tolerant to their dog leukocyte antigen-matched unaffected littermates through hematopoietic stem cell transplantation, intramuscular injection of donor marrow cells produced no evidence of dystrophin expression, and clonal